Erythroleukemia and other hematologic complications of intensive therapy in long‐term survivors of small cell lung cancer

Edward C. Bradley, Geraldine P. Schechter, Mary J. Matthews, Jacqueline Whang‐Peng, Martin H. Cohen, Paul A. Bunn, Daniel C. Ihde, John D. Minna

Research output: Contribution to journalArticlepeer-review

32 Citations (Scopus)

Abstract

Eight patients with small cell bronchogenic carcinoma treated with intensive combination chemotherapy, with and without radiotherapy, have been followed for a minimum of two and a half years without relapse. One patient, after a prodrome of macrocytic sideroblastic anemia, leukopenia, and thrombocytopenia, experienced erythroleukemia 34 months after starting chemotherapy, and cytogenetic studies revealed extensive chromosomal abnormalities. Another patient had persistent macrocytic anemia and pancytopenia two years after cessation of therapy. The remaining six patients have normal peripheral blood smears and cell counts. A significant incidence of preleukemic syndromes and acute leukemia appearing as late complications in intensively treated small cell lung cancer patients requires confirmation in larger series of long‐term survivors. Prospective determination of marrow karyotype abnormalities may help to identify patients at greatest risk for developing secondary leukemia.

Original languageEnglish
Pages (from-to)221-223
Number of pages3
JournalCancer
Volume49
Issue number2
DOIs
Publication statusPublished - Jan 1 1982
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Erythroleukemia and other hematologic complications of intensive therapy in long‐term survivors of small cell lung cancer'. Together they form a unique fingerprint.

Cite this